Charles Schwab Investment Management Inc. Acquires 135,051 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Charles Schwab Investment Management Inc. increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,539,934 shares of the company's stock after acquiring an additional 135,051 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.50% of Amneal Pharmaceuticals worth $12,196,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $81,000. Quest Partners LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $84,000. Janney Montgomery Scott LLC acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at $121,000. Quadrature Capital Ltd bought a new position in shares of Amneal Pharmaceuticals in the third quarter worth about $169,000. Finally, Entropy Technologies LP bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $259,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Finally, Barclays boosted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, March 3rd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $10.80.

Remove Ads

Amneal Pharmaceuticals Stock Down 4.0 %

Shares of NASDAQ AMRX traded down $0.36 during mid-day trading on Tuesday, reaching $8.53. 1,398,064 shares of the company were exchanged, compared to its average volume of 1,348,060. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.18 and a twelve month high of $9.48. The stock has a market capitalization of $2.64 billion, a P/E ratio of -12.54 and a beta of 1.05. The company's 50-day simple moving average is $8.40 and its 200-day simple moving average is $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the business posted $0.14 earnings per share. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the transaction, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,240,000 shares of company stock worth $43,754,000 in the last three months. 26.56% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.